Intarcia Therapeutics IPO

Intarcia is a biotech company dedicated to redesigning the treatment, prevention and experience of chronic disease.

Register for Details

For more details on financing and valuation for Intarcia Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Who are Intarcia Therapeutics's major investors?

New Enterprise Associates
GGV Capital
Venrock
Foresite Capital
Farallon Capital Management
Fred Alger Management
New Leaf Venture Partners
Quilvest
RA Capital

Intarcia Therapeutics Funding Rounds and IPO Valuation

Date Funding Round Funding Raised Price per Share IPO Valuation
9/15/2016 Series EE $3.94B $XXX.XX $XXX.XX
7/4/2014 Series DD $1.63B $XXX.XX $XXX.XX
11/15/2012 Series CC $612MM $XXX.XX $XXX.XX
1/14/2010 Series BB-3 $138MM $XXX.XX $XXX.XX
4/28/2008 Series BB-2 $112MM $XXX.XX $XXX.XX
3/9/2007 Series BB-1 $103.02MM $XXX.XX $XXX.XX
12/1/2004 Series AA $98MM $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data

Learn more about Intarcia Therapeutics

Forge green plus iconForge green minus icon

What is Intarcia Therapeutics funding to date?

Intarcia Therapeutics has raised $961.46MM with the following series:
$98MM for Series AA, $103.02MM for Series BB-1, $112MM for Series BB-2, $138MM for Series BB-3, $612MM for Series CC, $1.63B for Series DD, $3.94B for Series EE, $98MM for Series AA, $103.02MM for Series BB-1, $112MM for Series BB-2, $138MM for Series BB-3, $612MM for Series CC, $1.63B for Series DD, $3.94B for Series EE.